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Abstract
Aims/hypothesis LARS2 has been previously identified as a
potential type 2 diabetes susceptibility gene through the
low-frequency H324Q (rs71645922) variant (minor allele
frequency [MAF] 3.0%). However, this association did not
achieve genome-wide levels of significance. The aim of this
study was to establish the true contribution of this variant
and common variants in LARS2 (MAF>5%) to type 2
diabetes risk.
Methods We combined genome-wide association data (n=
10,128) from the DIAGRAM consortium with independent
data derived from a tagging single nucleotide polymor-
phism (SNP) approach in Dutch individuals (n=999) and
took forward two SNPs of interest to replication in up to
11,163 Dutch participants (rs17637703 and rs952621). In
addition, because inspection of genome-wide association
study data identified a cluster of low-frequency variants
with evidence of type 2 diabetes association, we attempted
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replication of rs9825041 (a proxy for this group) and the
previously identified H324Q variant in up to 35,715
participants of European descent.
Results No association between the common SNPs in
LARS2 and type 2 diabetes was found. Our replication
studies for the two low-frequency variants, rs9825041 and
H324Q, failed to confirm an association with type 2
diabetes in Dutch, Scandinavian and UK samples (OR
1.03 [95% CI 0.95–1.12], p=0.45, n=31,962 and OR 0.99
[0.90–1.08], p=0.78, n=35,715 respectively).
Conclusions/interpretation In this study, the largest study
examining the role of sequence variants in LARS2 in type 2
diabetes susceptibility, we found no evidence to support
previous data indicating a role in type 2 diabetes susceptibility.
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Introduction
Changes in mitochondrial function are observed in patients
with type 2 diabetes and their first-degree relatives.
Previous studies have indicated that genes involved in
oxidative phosphorylation are downregulated in the muscle
cells of type 2 diabetes patients [1]. Furthermore, the
muscle mitochondria from patients with type 2 diabetes
have an impaired bioenergetic capacity [2]. Mitochondria
also play an important role in insulin secretion and
sensitivity [3, 4]. Previously, our group has shown that a
mutation in the mitochondrial DNA-encoded tRNA-Leu
(UUR), encoded by the MT-TL1 gene is associated with
maternally inherited diabetes and deafness [5]. In addition,
an H324Q (rs71645922) variant in the nuclear encoded
mitochondrial LARS2 gene has shown an association with
type 2 diabetes in work previously carried out by our
group [6]. The LARS2 gene encodes for the mitochondrial
leucyl tRNA synthetase (EC 6.1.1.4), which catalyses the
aminoacylation of both mitochondrial leucyl tRNAs with
leucine and is therefore essential for mitochondrial protein
synthesis. By analysing the coding region for the LARS2
gene, we found the H324Q (rs71645922) variant and
demonstrated an association with type 2 diabetes suscep-
tibility in a meta-analysis of four independent cohorts
from the Netherlands and Denmark (OR 1.40 [95% CI
1.12–1.76], p=0.004, n=7,836) [6].
In recent years the advent of genome-wide association
studies (GWAS) and the accumulation of large data sets
capable of detecting associations to levels of genome-wide
significance appropriate for such studies (p<5×10−8) have
identified close to 20 loci impacting on type 2 diabetes
susceptibility. However, low-frequency variants such as
H324Q are generally poorly captured by such studies. We
set out therefore to re-evaluate the possible contribution of
this low-frequency variant to type 2 diabetes susceptibility
in appropriately sized samples. We also used a combination
of publicly available (DIAGRAM consortium: www.well.
ox.ac.uk/DIAGRAM/, accessed 2 May 2008) and newly
derived tagging single nucleotide polymorphism (SNP) data
to undertake the most comprehensive assessment of the
LARS2 locus yet performed.
Methods
Study samples The first part of our study aimed to identify
common alleles associated with increased type 2 diabetes
susceptibility using DIAGRAM consortium data and a
tagging SNP approach. For this we genotyped several
European samples.
The first sample was from the Hoorn Study (NL1) [7], a
Dutch population-based study from the city of Hoorn, in
the north-west of the Netherlands, from which we selected
519 participants with normal glucose tolerance (NGT) and
480 type 2 diabetes patients. Glucose tolerance was
assessed using a fasting OGTT, according to 1999 WHO
criteria [8]. This sample was used to analyse common
variation in LARS2 gene with a tagging SNP approach.
Variants in LARS2 identified from the DIAGRAM meta-
analysis and the tagging SNP approach were then taken
forward for replication in three Dutch samples.
The second Dutch sample (NL2) included 1,517 controls
and 821 type 2 diabetic patients [9, 10]. The 1,517 controls
were randomly selected from the New Hoorn Study (NHS),
which is an ongoing, population-based study from the city
of Hoorn which does not overlap with the original NL1
sample. Of the type 2 diabetes patients, 147 were from the
NHS and the remainder (n=674) were recruited from the
diabetes clinics of the Leiden University Medical Centre
and the Vrije Universiteit medical centre, Amsterdam. All
participants in this replication sample were Dutch whites.
All NGT participants underwent an OGTT and were
classified according to WHO criteria [8].
The third replication sample was ascertained from the
Breda study (NL3) [11, 12]. This is a case–control study
from the city of Breda, in the south of the Netherlands. The
920 controls were from the Dutch blood bank and self-
reported a non-diabetic state. The 501 cases had type 2
diabetes diagnosed on the basis of WHO criteria [8].
For the fourth replication sample we selected 5,183 NGT
participants and 1,222 type 2 diabetes patients from the
population-based ERGO study (NL4) from Rotterdam in
the south-west region of the Netherlands [13].
In total 8,139 controls and 3,024 type 2 diabetes patients
were included in our replication study in the Netherlands.
The second part of this study was focused on the follow
up of two low-frequency variants in LARS2, for which we
carried out replication in samples from the Netherlands
(NL1–NL4) as well as samples from the UK (UK sample 1
[UK1], UK sample 2 [UK2]), Denmark (Denmark sample 1
[DK1]), Finland (Finland sample 1 [FL1], Finland sample 2
[FL2]) and Sweden (Sweden [SE1]).
Our DK1 sample [14] consisted of 514 NGT controls
randomly selected from public registers at the Steno Diabetes
Center and the Research Centre for Prevention and Health,
Copenhagen, Denmark. The 706 type 2 diabetes patients were
recruited from the Steno Diabetes Center. NGT participants
underwent an OGTT according to WHO criteria [8].
Of the two UK samples, the first (UK1) was the United
Kingdom Type 2 Diabetes Genetics Consortium case–
control sample, comprising 4,124 type 2 diabetes patients
and 5,126 controls ascertained in Tayside, Scotland. Details
of the ascertainment scheme and recruitment criteria for this
sample have been described elsewhere [15, 16]. The
enlarged sample used here represents continuing recruit-
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ment to this resource under precisely the same criteria. The
second sample, UK2, consisted of 1,853 type 2 diabetes
patients ascertained as part of the BDAWarren 2 collection
(Exeter, London, Oxford, Norwich and Newcastle) and
10,220 control samples. The latter represent the full British
1,958 Birth Cohort (n=7,133) and the United Kingdom
Blood Services Collection of Common Controls (n=3,087),
a subset of which featured in theWellcome Trust Case Control
Consortium (WTCCC) genome-wide association scan (both
samples were collected throughout the UK) [15, 16].
Finally, we included samples from Finland and Sweden.
The FL1 sample was a case–control sample from the Botnia
region of Finland, consisting of 353 controls and 402 type 2
diabetes patients. The sample from Sweden, SE1, was from
a case–control study from Skara and Malmö, and consisted
of 468 controls and 480 type 2 diabetes patients. We also
included a set of trios originating from the Botnia region of
Finland. This sample, FL2, consisted of 211 probands
(multiple diabetic sibs) and 370 parents [17, 18]. All study
samples are summarised in Table 1.
In total 25,191 controls and 10,800 type 2 diabetes
patients were included for follow up of the low-frequency
variants.
All studies were approved by the appropriate medical
ethical committees and were in accordance with the
principles of the Declaration of Helsinki. All participants
provided written, informed consent for this study.
Common SNP selection Common SNPs (minor allele
frequency [MAF] >5%) in the LARS2 locus were selected
for follow-up based on data from the DIAGRAM meta-
analysis (gene boundaries chr3: 45373001 ... 45698001)
[19]. SNPs with a p<0.05 were genotyped in the Dutch
replication samples (NL1-NL4). Furthermore, tagging
SNPs in LARS2 were selected for genotyping in the NL1
sample using the HapMap database and Tagger software
[20, 21] (selection criteria and SNPs shown in Electronic
supplementary material [ESM] Table 1).
Genotyping and quality control SNPs selected for follow-
up in our replication samples were genotyped using Taqman
SNP genotyping assays (Applied Biosystems, Foster City,
CA, USA). Tagging SNPs were genotyped in the NL1
sample using the Sequenom platform (Sequenom, San
Diego, CA, USA). Assays showing overlapping clusters,
success rates below 95% or not obeying Hardy–Weinberg
equilibrium (p<0.05) were excluded from analysis. Dupli-
cate samples (∼5%) showed complete concordance.
Statistical analysis Differences in genotype distribution and
allele frequencies were analysed using a χ2 test. Odds ratios
were calculated using an additive model, which was the
best fit for the data. Homogeneity of ORs between the
different samples was calculated with a Tarone’s test, after
which a common OR was calculated with a Mantel–
Haenszel test using a fixed effects model. Results from
OGTT (only NGT participants) were analysed with univar-
iate analysis of variance, using additive, recessive and
dominant models, and correction for age, BMI and sex as
possible confounders. Association was assessed by the
transmission disequilibrium test in the Botnia trios. All
general statistics were calculated using SPSS 16.0 (SPSS,
Chicago, IL, USA). For statistics involving the geograph-
ical distribution of the H324Q (rs71645922) variant in the
UK population (described below), we used StatXact v 6.0
(Cytel Software, Cambridge, MA, USA).
Power calculations were performed using Quanto [22].
From the DIAGRAM consortium meta-analysis of common
variants we selected for replication all common SNPs with
a p<0.05. At this alpha, the DIAGRAM consortium meta-
analysis had at least 80% power to detect a variant with
OR≥1.20 (MAF>0.05) [22]. Combined with our Dutch
Study Participants, n (% male) Mean age, years (SD) Mean BMI , kg/m2 (SD)
Controls Cases Controls Cases Controls Cases
NL1 519 (55) 480 (52) 65 (8) 67 (8) 26.4 (4.5) 28.8 (4.6)
NL2 1,517 (44) 821 (50) 53 (7) 61 (11) 25.5 (3.6) 29.0 (4.6)
NL3 920 (61) 501 (46) 48 (13) 71 (10) n.a. 27.8 (4.1)
NL4 5,183 (41) 1,222 (39) 69 (9) 73 (9) 26.0 (3.9) 27.4 (4.0)
DK1 514 (46) 706 (48) 57 (10) 59 (10) 25.9 (3.8) 29.3 (5.1)
UK1 5,126 (51) 4,124 (55) 60 (13) 66 (6) 26.9 (11.4) 31.2 (13.8)
UK2 10,220 (50) 1,853 (61) 42 (7) 57 (9) 27.2 (6.4)a 31.8 (6.7)
FL1 353 (53) 402 (55) 60 (10) 61 (10) 26.1 (3.6) 28.7 (4.5)
FL2 370 (50)b 211 (47)c n.a. 40 (9) 28.5 (5.5) n.a.
SE1 468 (52) 480 (53) 66 (12) 67 (11) 27.5 (4.1) 27.9 (4.1)
Table 1 Description of study
samples
a Based on the British 1958
Birth Cohort (n=7,133) and
Panel 2 of the United Kingdom
Blood Services Collection of
Common Controls (n=1,643)
b Parents
c Probands
n.a., not available
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replication sample, we had at least 80% power to replicate
the association of a variant with an OR≥1.09 at the observed
MAFs of 0.19 (rs952621) and 0.24 (rs17637703) respec-
tively (α=0.05 or OR≥1.12 at α=10−4). Power of the
tagging SNP approach in NL1 was limited (80% power to
detect a variant with an OR≥1.6 [α=0.05, MAF=0.05] or
OR≥1.45 at the observed lowest MAF of 0.10). Therefore
we replicated in NL2-NL4 only our strongest signal from
the NL1 sample (rs17637703, p=0.07).
While extensive GWAS have indicated that the effect
sizes of common variants influencing type 2 diabetes risk
are modest, the potential remains for low-frequency
variants to have effects on type 2 diabetes risk that are
more substantial, which was corroborated by our previous
observation regarding the H324Q variant [6]. Power
calculations at the start of the project demonstrated that
we had at least 99% power to detect an effect size similar to
our initial finding for H324Q (rs71645922) (OR 1.4) and at
least 80% power to detect an OR of 1.13 (α=0.05) [6].
From the DIAGRAM meta-analysis we used an alpha of
0.05 to select other low-frequency SNPs for replication. At
this alpha, the power in DIAGRAM was 80% to detect
association for variants with ORs ranging from 1.24
(MAF=0.03) to 1.45 (MAF=0.01 and α=0.05). For
replication of the two low-frequency variants (observed
MAFs ∼0.03 [H324Q, rs71645922] and ∼0.05 [rs9825041]
respectively), we had in our complete replication sample at
least 80% power to detect an OR≥1.13 (25,191 controls
and 10,800 type 2 diabetes patients, α=0.05).
Results
Common LARS2 variants in available DIAGRAM GWAS
data We analysed the data from the DIAGRAM GWAS
meta-analysis [19] for the LARS2 gene (100% coverage
[MAF>5%], according to HapMap phase 2, April 2007,
Centre d’Etude du Polymorphisme [Utah residents with
northern and western European ancestry] [CEU] population)
and observed one common SNP (rs952621, directly typed)
showing weak evidence of association with type 2 diabetes
(OR 1.11 [95% CI 1.02–1.20], p=0.01 for the T allele). This
SNP was also captured in our complementary tagging SNP
approach (NL1), with an OR of 1.13 [95% CI 0.89–1.43],
p=0.33 for the same allele. However, additional genotyping
in the Dutch samples (NL2, NL4) and meta-analysis of all
data resulted in a common OR of 1.05 (0.99–1.11, p=0.13,
n=19,870). As there was no convincing evidence of asso-
ciation in our samples, this SNP was not analysed further.
No other common SNP in LARS2 showed evidence of
association with type 2 diabetes in the GWAS data. The
same was true of the tagging SNP analysis conducted in the
NL1 sample (ESM Table 1). In the latter analysis,
rs17637703 showed weak evidence of association (OR
1.22 [95% CI 0.99–1.50], p=0.07), but this was not
confirmed in the Dutch replication samples (common OR
0.98 [95% CI 0.91–1.06], p=0.62, n=10,087), in line with
the DIAGRAM result for this SNP (OR 1.02 [0.94–1.10]).
Low-frequency variants in LARS2 In addition to the
common variants, the DIAGRAM meta-analysis also
captured fourteen low-frequency SNPs (0.01>MAF<0.05)
within the LARS2 gene, ten of which are in high linkage
disequilibrium with each other (r2>0.95 according to
HapMap) (ESM Fig. 1) and showed some evidence for
association with type 2 diabetes (ORs 1.17–1.21; p 0.02–
0.05). We selected rs9825041 (OR 1.20 [95% CI 1.03–
1.39], p=0.02) as a proxy for the group for genotyping in
the replication samples, but no association with type 2
diabetes was observed (Table 2). Homogeneity of ORs was
tested with a Tarone’s test (p=0.67) and we calculated a
common OR across all studies of 1.03 (95% CI 0.95–1.12),
p=0.45 (8,959 type 2 diabetic patients, 23,003 controls).
Follow up of the H324Q (rs71645922) variant in
LARS2 Finally, we examined the association of the
H324Q (rs71645922) variant with type 2 diabetes in our
replication samples NL2 to NL4, UK1 and UK2, SE1 and
FL1. This variant was not captured by the GWAS and was
not captured by any of the SNPs mentioned above (r2<
0.17). Participants in the Dutch replication samples includ-
ed in our original study of this variant were excluded from
analysis (n=914 from NL4 study). The replication samples
did not confirm our previously observed association. A
meta-analysis of all available studies including our previous
data from the Netherlands (NL1) and Denmark (DK1,
DK2) [6] resulted in an overall OR of 0.99 (95% CI 0.90–
1.08), p=0.78, n=35,715 participants (10,399 type 2
diabetes patients) (Table 2). In addition, no significant
excess of transmission of the risk allele was observed in the
Botnia trios (FL2, transmitted/untransmitted=18/14, OR
1.29 [95% CI 0.64–2.59], p=0.48).
To investigate possible heterogeneity between the stud-
ies, we performed several analyses. For age stratification
we created, based on the age distribution in the Dutch
samples, the following age strata: ≤60 years, 61 to 70 years
and >70 years. A decreased frequency of the risk allele was
observed in type 2 diabetes participants with increasing age
in most but not all samples (data not shown, available on
request), but this did not reach statistical significance. We
also looked at age at diagnosis of type 2 diabetes and allele
frequencies in those with early-onset diabetes (≤45 years)
and in those with age at diagnosis above 45 years.
Although the allele frequency was slightly higher in those
with early-onset diabetes, this was not statistically signif-
icant, nor was the age at diagnosis in carriers and non-
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carriers (all p>0.05, data not shown). Stratification for sex
and BMI (where data available) did not affect the outcome
in the Dutch studies (NL1-NL4, data not shown) and was
therefore not further investigated.
H324Q (rs71645922) shows marked variation in MAF
between the various European-descent samples examined
(control MAF ranges from 1.9 to 4.8%). In the two large
UK control samples, for example, there was a highly
significant (p=5×10−7, using an exact implementation of
the Cochran–Armitage trend test) difference in allele
frequencies between UK1 (recruited exclusively in Scot-
land) and UK2 (recruited throughout the UK), which made
us consider the possibility that this variant showed variation
in allele frequency along the south–north cline as previ-
ously described in the WTCCC study and others [16, 23–
26]. To test this, we used information on the region of
ascertainment that was available from the UK 1958 Birth
Cohort and UK Blood Service, and analysed genotype
frequencies based on subdivisions of the UK into four
major regions, namely (1) Scotland, (2) northern England,
(3) Midlands and (4) southern England (see ESM Fig. 2).
We found some evidence (ESM Fig. 2) for a north–south
gradient across the UK (MAF 4.66%, 3.41%, 3.31% and
3.28% from north to south respectively, with p=0.038,
calculated using the Jonckheere–Terpstra Test [StatXact]).
No such MAF gradient was observed in other European
samples (ESM Fig. 3)
Discussion
We found no evidence of common SNPs in LARS2 being
associated with type 2 diabetes in our samples. We
therefore conclude that it is unlikely that common SNPs
in LARS2 are associated with type 2 diabetes susceptibility.
Several low-frequency SNPs, all in high linkage dis-
equilibrium with each other (r2>0.95), showed nominal
evidence of association with type 2 diabetes in the
DIAGRAM meta-analysis. However, we have been unable
to confirm this association in our large replication samples
from the Netherlands, Denmark and the UK (n=31,962).
We therefore conclude that the nominal p values observed
in the GWAS are most likely to be consistent with statistical
noise.
The previously observed association of the H324Q
(rs71645922) variant in LARS2 with type 2 diabetes was
not confirmed in our replication samples (Table 2). Power
calculations at the start of the project demonstrated that we
had at least 99% power to detect an effect size similar to
our initial finding for H324Q (rs71645922) (OR 1.4) and at
least 80% power to detect an OR of 1.13. Before excluding
the previous association as false, we considered the
possibility of heterogeneity, but found no evidence that
age, age at diagnosis, BMI and sex were responsible.
Another possibility, raised by the evidence for clinal
variation in H324Q MAF across the UK, is that the previous
Table 2 Genotyping results for rs9825041 and H324Q (rs71645922)
Sample Controls/cases rs9825041 H324Q (rs71645922)
MAF
controls
(%)
MAF
cases
(%)
OR
(95% CI)
pAdd MAF
controls
(%)
MAF
cases
(%)
OR
(95% CI)
pAdd
NL1 519/480 5.5 7.3 1.35 (0.92–1.98) 0.15 1.9 4.3 2.26 (1.10–4.66)a 0.04
NL2 1,517/821 6.0 6.6 1.11 (0.85–1.44) 0.46 3.4 2.7 0.78 (0.49–1.25) 0.18
NL3 920/501 5.7 6.8 1.21 (0.88–1.66) 0.25 3.3 3.0 0.90 (0.57–1.41) 0.74
NL4 5,183/1,222 6.1 5.5 0.89 (0.74–1.08) 0.27 3.1 3.5 1.11 (0.84–1.47)a 0.47
DK1 514/706 4.2 4.7 1.12 (0.75–1.68) 0.62 2.2 2.8 1.24 (0.74–2.09)a 0.44
DK2 4,501/654 n.m. n.m. n.m. n.m. 2.8 3.7 1.33 (0.97–1.82)a 0.08
UK1 5,126/4,124 4.9 4.9 1.00 (0.87–1.14) 1.00 4.8 4.4 0.91 (0.79–1.05) 0.19
UK2 10,220/1,853 4.8 5.1 1.05 (0.88–1.27) 0.57 3.6 3.4 0.94 (0.77–1.15) 0.59
FL1 353/402 n.m. n.m. n.m. n.m. 4.2 4.9 1.18 (0.72–1.93) 0.51
SE1 468/480 n.m. n.m. n.m. n.m. 4.5 4.2 0.94 (0.59–1.48) 0.79
Meta-analysis 1.03 (0.95–1.12) 0.48 0.99 (0.90–1.08) 0.82
DIAGRAM
GWASb
1.20 (1.03–1.39) 0.02 NM NM
aData from previously published results [6]; results from NL4 study are partially from this previous research (n=914)
bMeta-analysis of the DIAGRAM consortium GWAS, n=10,128 (4,549 type 2 diabetic patients, 5,579 controls) [19]
n.m., not measured
pAdd, p value, additive model
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association in Dutch and Danish participants reflected the
effects of hidden population structure. However, it seems
unlikely that population stratification effects were respon-
sible for the original reports of H324Q (rs71645922)
associations, as the cases and controls in that study were
recruited from the same relatively narrow geographic
regions within the Netherlands and Denmark [6]. Also in
our additional Dutch replication cohorts we could not detect
a MAF gradient across the country. However, there are
differences in MAF between different countries (ESM Figs 2
and 3). Migration patterns in the UK appear to reflect an
increase in the MAF of H324Q (rs71645922) and therefore
this may be a potential migration marker. However, this
needs to be demonstrated in other populations. Since
stratification for BMI and sex did not affect our result, we
can exclude the possibility that these variables confounded
our observation. The reason for the discrepancy between our
first and current study is likely to be chance.
Three other low-frequency non-synonymous SNPs are
present in the LARS2 locus: K727N (rs36054230), E831D
(rs9827689) and E868K (rs34965084). However, according
to the dbSNP database and our own sequencing efforts [6],
these SNPs are only identified in the African population
and not polymorphic in the European population. There-
fore, these additional non-synonymous variants were not
analysed in this study. As our study did not include a thorough
resequencing of the complete LARS2 locus, we cannot fully
exclude that other, as yet unknown low-frequency variants
are present and associated with type 2 diabetes. Results from
the 1,000 genomes project (www.1000genomes.org) should
facilitate a thorough investigation of low-frequency SNPs in
LARS2 in the future.
In conclusion, our findings do not support the hypothesis
that common variants in LARS2 are major type 2 diabetes
susceptibility factors. We have also conducted one of the
largest (up to 35,715 participants) replication studies for two
low-frequency variants for type 2 diabetes susceptibility.
These variants also do not play a significant role in type 2
diabetes susceptibility. We therefore conclude that currently
known genetic variation in LARS2 does not play an
important role in type 2 diabetes susceptibility.
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